This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Recombinant Equine Insulin-like Growth Factor I (IGF1)
Product Overview
BioVenic's Recombinant Equine Insulin-like Growth Factor I (IGF1) is a recombinant protein expressed from E. coli expression system. Its predicted molecular weight is 7 kDa. The purity is greater than 95% (SDS-PAGE). The endotoxin level is <0.5 EU/μg (LAL).
Specifications
Target Information
Insulin-like growth factor I (IGF1) belongs to the family of insulin-like growth factors that are structurally homologous to proinsulin. It may be a physiological regulator of [1-14C]-2-deoxy-D-glucose (2DG) transport and glycogen synthesis in osteoblasts. It stimulates glucose transport in bone-derived osteoblastic (PyMS) cells and is effective at much lower concentrations than insulin, not only with respect to glycogen and DNA synthesis, but also with respect to enhancing glucose uptake. In a horse model, a negatively asynchronous uterine environment retarded IGF1, IGF2 and INSR expression in the conceptus, whereas in the endometrium only INSR expression was altered by asynchrony.
Shipping and Storage
This product is shipped with dry ice. It is recommended to aliquote as needed and store at -20°C upon receipt. Reconstituted protein solution can be stored at 4°C for 1 week, at < -20°C for 3 months.
Documents
The product is for research use only.
Not for commercial, prophylactic, diagnostic, or therapeutic applications.
User Note
- Always centrifuge tubes before opening. Dissolve the lyophilized protein in distilled water. Avoid mixing by vortexing or pipetting. It is not recommended to reconstitute to a concentration < 100 μg/mL. Aliquote the reconstituted solution to minimise freeze-thaw cycles.
References
- Gibson, C. et al. Insulin-like growth factor system components expressed at the conceptus-maternal interface during the establishment of equine pregnancy. Front Vet Sci. 2022, 9: 912721.